Advanced Filters
noise

Durham, North Carolina Clinical Trials

A listing of Durham, North Carolina clinical trials actively recruiting patient volunteers.

Found 623 clinical trials
F Felicia A Browne, ScD, MPH

Gathering Online for Dialogue and Discussion to Enhance Social Support

The goal of this trial is to test a modified mobile health intervention (with a group component) relative to a mobile health intervention in a two-arm randomized trial with 500 young African American women who are human immunodeficiency virus (HIV)-negative and who misuse alcohol. The expected outcomes are to: (1) …

18 - 30 years of age All Phase N/A
C Clinical Research Coordinator

Opioids, Low Nicotine Cigarettes, and Chronic Pain

The purpose of this study is to evaluate the effects of switching to very low nicotine content (VLNC) cigarettes versus normal nicotine content (NNC) cigarettes on craving, withdrawal, and pain among individuals with chronic pain who smoke cigarettes daily and are attending office-based buprenorphine treatment (OBBT).

21 years of age All Phase N/A

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort B: Participants will be randomized to receive either a placebo or paridiprubart. This record …

18 years of age All Phase 2
L Lisa Einhorn

Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia

The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following tonsillectomy surgery in children and adolescents.

3 - 17 years of age All Phase 4
A Antoinette Swanson

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

2 - 17 years of age All Phase 3

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

This is an open-label phase I study of fostamatinib in combination with ruxolitinib for the treatment of chronic GvHD with a suboptimal response to corticosteroids. The primary objective is to identify a minimum safe and biologically effective dose of fostamatinib when combined with standard of care ruxolitinib for the treatment …

18 - 80 years of age All Phase 1
S Smrithi Divakaran, MPH

Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors

The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended follow-up care.

18 - 39 years of age All Phase N/A
S Sophia Smith, PhD

Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors

The purpose of this study is to evaluate the feasibility and acceptability of the Mindset Moments™ (MM™) program in managing psychological distress and resiliency in adolescent and young adult cancer survivors. Study participation will involve attending 8 weekly, one hour, live online group sessions and completing daily 5 minute activities …

19 - 25 years of age All Phase N/A
C Charlotte Ready, PhD

Evaluating Treatments for Suicidal Veterans With PTSD

Posttraumatic Stress Disorder (PTSD) is a significant driver of suicide risk among Veterans, but there is a critical knowledge gap about how to treat PTSD among people at elevated risk for suicide. Although evidence-based treatments for PTSD reduce suicide risk, Veterans at high risk for suicidal behavior rarely receive these …

18 years of age All Phase N/A
T Toby Maher

Platform Clinical Study for Conquering Scleroderma

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.

18 years of age All Phase 2

Simplify language using AI